WO2004029285A3 - Methods for detecting endocrine cancer - Google Patents

Methods for detecting endocrine cancer Download PDF

Info

Publication number
WO2004029285A3
WO2004029285A3 PCT/CA2003/001478 CA0301478W WO2004029285A3 WO 2004029285 A3 WO2004029285 A3 WO 2004029285A3 CA 0301478 W CA0301478 W CA 0301478W WO 2004029285 A3 WO2004029285 A3 WO 2004029285A3
Authority
WO
WIPO (PCT)
Prior art keywords
kallikrein
proteins
endocrine cancer
methods
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/001478
Other languages
French (fr)
Other versions
WO2004029285A2 (en
Inventor
George Yousef
Eleftherios P Diamandis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mt Sinai Hospital
Original Assignee
Mt Sinai Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mt Sinai Hospital filed Critical Mt Sinai Hospital
Priority to CA002499261A priority Critical patent/CA2499261A1/en
Priority to US10/529,163 priority patent/US20060223059A1/en
Priority to AU2003271456A priority patent/AU2003271456A1/en
Priority to JP2004538614A priority patent/JP2006500036A/en
Priority to EP03753165A priority patent/EP1546728A2/en
Publication of WO2004029285A2 publication Critical patent/WO2004029285A2/en
Publication of WO2004029285A3 publication Critical patent/WO2004029285A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Kallikrein (12), kallikrein (14), and kallikrein (15) proteins, and nucleic acids encoding the proteins have particular application in the detection of endocrine cancer, in particular ovarian cancer. Kallikrein (12), kallikrein (14), and kallikrein (15) proteins and nucleic acid molecules encoding the proteins constitute new biomarkers for diagnosis and monitoring (i.e. monitoring progression or therapeutic treatment) of endocrine cancer.
PCT/CA2003/001478 2002-09-26 2003-09-26 Methods for detecting endocrine cancer Ceased WO2004029285A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002499261A CA2499261A1 (en) 2002-09-26 2003-09-26 Methods for detecting endocrine cancer
US10/529,163 US20060223059A1 (en) 2002-09-26 2003-09-26 Methods for detecting endocrine cancer
AU2003271456A AU2003271456A1 (en) 2002-09-26 2003-09-26 Methods for detecting endocrine cancer
JP2004538614A JP2006500036A (en) 2002-09-26 2003-09-26 Method for detecting endocrine cancer
EP03753165A EP1546728A2 (en) 2002-09-26 2003-09-26 Methods for detecting endocrine cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41410702P 2002-09-26 2002-09-26
US60/414,107 2002-09-26
US45092803P 2003-02-27 2003-02-27
US60/450,928 2003-02-27

Publications (2)

Publication Number Publication Date
WO2004029285A2 WO2004029285A2 (en) 2004-04-08
WO2004029285A3 true WO2004029285A3 (en) 2004-08-19

Family

ID=32045271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001478 Ceased WO2004029285A2 (en) 2002-09-26 2003-09-26 Methods for detecting endocrine cancer

Country Status (6)

Country Link
US (1) US20060223059A1 (en)
EP (1) EP1546728A2 (en)
JP (1) JP2006500036A (en)
AU (1) AU2003271456A1 (en)
CA (1) CA2499261A1 (en)
WO (1) WO2004029285A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
WO2002014485A2 (en) 2000-08-11 2002-02-21 Mount Sinai Hospital Kallikrein gene
ATE365922T1 (en) * 2000-10-27 2007-07-15 Mount Sinai Hospital Corp METHOD FOR DETECTING Ovarian CANCER USING HUMAN KALLIKREIN (HK6)
JP2004512540A (en) * 2000-11-01 2004-04-22 マウント・サイナイ・ホスピタル Ovarian cancer detection
US20040203012A1 (en) * 2001-05-25 2004-10-14 Eleftherios Diamandis Method of detecting and monitoring prostate and ovarian cancers
CA2463920A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Methods for detecting ovarian cancer
CA2497061A1 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
AU2003269618A1 (en) * 2002-08-28 2004-03-19 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
CA2516591A1 (en) * 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
WO2004077060A2 (en) * 2003-02-27 2004-09-10 Mount Sinai Hospital Assay for detection of renal cell carcinoma
US20060269971A1 (en) * 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1711616A1 (en) * 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 15 (klk15)
EP1711601A1 (en) * 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 12 (klk12)
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
ATE510492T1 (en) * 2006-06-05 2011-06-15 Forth Photonics Ltd METHOD FOR LABELING TISSUES
EP2087152B1 (en) * 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
JP2008278798A (en) * 2007-05-10 2008-11-20 Tokyo Medical & Dental Univ Method for detecting bladder cancer
WO2010009368A2 (en) * 2008-07-18 2010-01-21 Oragenics, Inc. Compositions for the detection and treatment of colorectal cancer
CN113884685B (en) * 2021-10-18 2023-03-14 中国农业大学 Bovine tuberculosis serological diagnosis marker and clinical application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037112A2 (en) * 2000-11-01 2002-05-10 Mount Sinai Hospital Detection of ovarian cancer
WO2003034068A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Localization of disorders associated with kallikreins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
WO2002014485A2 (en) * 2000-08-11 2002-02-21 Mount Sinai Hospital Kallikrein gene
CA2360219A1 (en) * 2000-10-27 2002-04-27 Mount Sinai Hospital Method for detecting alzheimer's disease
ATE365922T1 (en) * 2000-10-27 2007-07-15 Mount Sinai Hospital Corp METHOD FOR DETECTING Ovarian CANCER USING HUMAN KALLIKREIN (HK6)
US20040203012A1 (en) * 2001-05-25 2004-10-14 Eleftherios Diamandis Method of detecting and monitoring prostate and ovarian cancers
CA2463920A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Methods for detecting ovarian cancer
US20050287528A1 (en) * 2002-04-04 2005-12-29 Mount Sinai Hospital Methods for detecting ovarian cancer
AU2003269618A1 (en) * 2002-08-28 2004-03-19 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
CA2497061A1 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
WO2004077060A2 (en) * 2003-02-27 2004-09-10 Mount Sinai Hospital Assay for detection of renal cell carcinoma
CA2468651A1 (en) * 2003-06-13 2004-12-13 Eleftherios P. Diamandis Detection of neurodegenerative diseases
US20060269971A1 (en) * 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037112A2 (en) * 2000-11-01 2002-05-10 Mount Sinai Hospital Detection of ovarian cancer
WO2003034068A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Localization of disorders associated with kallikreins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIAMANDIS E P ET AL: "THE NEW HUMAN KALLIKREIN GENE FAMILY: IMPLICATIONS IN CARCINOGENESIS", TRENDS IN ENDOCRINOLOGY AND METABOLISM, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 11, no. 2, 2000, pages 54 - 60, XP000910866, ISSN: 1043-2760 *
YOUSEF G M ET AL: "KLK12 Is a Novel Serine Protease and a New Member of the Human Kallikrein Gene Family-Differential Expression in Breast Cancer", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 69, no. 3, 1 November 2000 (2000-11-01), pages 331 - 341, XP004437785, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
CA2499261A1 (en) 2004-04-08
AU2003271456A8 (en) 2004-04-19
EP1546728A2 (en) 2005-06-29
WO2004029285A2 (en) 2004-04-08
JP2006500036A (en) 2006-01-05
US20060223059A1 (en) 2006-10-05
AU2003271456A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
WO2004029285A3 (en) Methods for detecting endocrine cancer
WO2002008285A3 (en) Il-17 molecules and uses thereof
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2003033731A3 (en) Methods for detecting ovarian cancer
DE60138715D1 (en) TNF-RECEPTOR-SIMILAR MOLECULES AND THEIR APPLICATIONS
WO2006110599A3 (en) Cacna1e in cancer diagnosis, detection and treatment
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
WO2003000844A3 (en) Protein modification and maintenance molecules
WO2003004681A3 (en) Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
WO2004038412A3 (en) Method for detecting halitosis
WO2003048734A3 (en) Detection of matrix metalloproteinase rna in plasma and serum
PL374550A1 (en) Il-17 like molecules and uses thereof
AU2002317458A1 (en) Efficient methods for assessing and validating candidate protein-based therapeutic molecules encoded by nucleic acid sequences of interest
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
AU2002258630A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
EP1241269A3 (en) Method for detecting REG-like protein and nucleic acids coding therefor
WO2004045371A3 (en) Methods for diagnosing the presence or stage of cancer
AU2003298570A1 (en) Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
DE60309879D1 (en) Procedure for the diagnosis of cancer
AU2002303137A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002257075A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2002100896A3 (en) Method for diagnosing cancer susceptibility
WO2004018702A3 (en) Nphp nucleic acids and proteins
WO2005017109A3 (en) Nucleic acids and polypeptides required for cell survival in the absence of rb
WO2004017926A3 (en) Use of novel cytokine receptors as biomarkers and therapeutic targets in human cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2499261

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004538614

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003753165

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003753165

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006223059

Country of ref document: US

Ref document number: 10529163

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10529163

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003753165

Country of ref document: EP